All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Effects Of Emblica Officinalis Commercial Formulation In Type 2 Diabetic Patients

Author(s): R. H Chandra, C Veeresham, K Asres

The levels of blood glucose and malondialdehyde in type 2 diabetic patients have been studied after the administration of amalakic capsules containing 250 mg fruit powder of Emblica officinalis twice a day for 60 d. It was observed that the drug treatment decreases blood glucose levels from 203±82 mg/dl (initial) to 189±255.2 mg/dl (after 60 d of treatment). However, the decrease was statistically insignificant (p>0.05). On the other hand, administration of amalaki for the same period of time resulted in a significant decrease in malondialdehyde levels from 7.55±2.3 nM (initial) to 5.36±0.8 nM (after 60 d of treatment). The decrease in the levels of the malondialdehyde was statistically significant (p<0.05). In the present study, no direct relationship was observed between blood glucose levels and malondialdehyde levels (lipid peroxide levels) of type 2 diabetic patients.